How Well a New Injection Works Compared to IV
Treatments studied
This study tests a new medicine called empasiprubart that can be injected under the skin using an autoinjector (like an EpiPen). Researchers want to see how much of the medicine gets into your bloodstream and whether the injection works as well as an IV infusion. You'll be a healthy volunteer helping them understand if this new delivery method is effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You weigh between 110 and 264 pounds (50–120 kg)
- Your body mass index (BMI) is between 18 and 35
- You are in good general health with no serious medical or mental health conditions
- You have not been diagnosed with lupus (SLE) and certain lupus blood tests must be negative
- You have never received empasiprubart in a previous clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two methods of giving the drug efgartigimod under the skin in healthy adults. It helps ensure both methods work the same way, which may make treatment easier for patients in the future.
This study tests how a single injection of adimanebart is absorbed by the body and how it travels through the bloodstream. It is for healthy adults to help understand the drug's behavior.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This trial tests a new medicine called empasiprubart in teenagers ages 12–17 with CIDP, a rare nerve disease that causes weakness and numbness. Researchers want to find the right dose and see if it safely reduces symptoms.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
Hear when a new Healthy Volunteers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.